LGND peer analysis
Ligand Pharmaceuticals (LGND) against its competitors: price, today's move, 1-year return and market value side by side.
LGND and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABBV AbbVie | $289.00 | -2.00% | 26.64% | $521.11B |
| AMGN Amgen | $466.80 | 0.17% | 59.86% | $251.94B |
| BCRX BioCryst | $8.24 | -2.66% | 13.72% | $2.16B |
| BMY Bristol-Myers Squibb | $63.29 | 1.30% | 38.73% | $127.71B |
| EXEL Exelixis | $70.09 | 1.02% | 80.01% | $16.93B |
| GMAB Genmab | $54.93 | -3.73% | 91.59% | $35.09B |
| INCY Incyte | $119.99 | -0.33% | 29.59% | $24.54B |
| PFE Pfizer | $31.01 | 1.61% | 27.67% | $173.95B |
| RIGL Rigel Pharmaceuticals | $51.31 | -0.27% | 62.27% | $958.46M |
| LGND Ligand Pharmaceuticals | $307.23 | -4.81% | 64.24% | $6.43B |
- LGND's peers: ABBV (AbbVie), AMGN (Amgen), BCRX (BioCryst), BMY (Bristol-Myers Squibb), EXEL (Exelixis), GMAB (Genmab), INCY (Incyte), PFE (Pfizer).
Updated 2026-11-03 02:04 UTC